arrow
G

Gerald F. Watts

University of Western Australia
H指数:124
被引数:7.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Integration of lipidomic and polygenic risk scores within contemporary clinical cardiovascular risk assessment pathways: a multi-cohort development and validation study

脂质组学和多基因风险评分在当代临床心血管风险评估路径中的整合:一项多队列开发与验证研究

2026-08-010
OAAI
Familial hypercholesterolaemia in children and adolescents: a European Atherosclerosis Society consensus statement

儿童和青少年家族性高胆固醇血症:欧洲动脉粥样硬化学会共识声明

2026-05-250
OA
Low-plastic diet and urinary levels of plastic-associated phthalates and bisphenols: the randomized controlled PERTH Trial

低塑料饮食和尿液中与塑料相关的邻苯二甲酸酯和双酚水平: 随机对照珀斯试验

2026-04-210
OAAI
Zodasiran for cholesterol and triglyceride lowering in patients with hyperlipidemia: final report of phase 1 basket trial

Zodasran降低高脂血症患者的胆固醇和甘油三酸酯: 1期篮子试验的最终报告

2026-04-070
PRE
Barriers and Facilitators to Implementing Guideline Recommendations for Key Aspects of Familial Hypercholesterolemia Management in Australia: Primary Care Integration, Paediatric Management, and Treatment Adherence

澳大利亚在家族性高胆固醇血症管理关键方面的指南建议实施障碍与促进因素:初级保健整合、儿科管理和治疗依从性

2026-04-010
PRE
Attainment of Low-Density Lipoprotein Cholesterol Goals and Statin Use in Patients With Atherosclerotic Cardiovascular Disease in Australian General Practice: Are We Doing Enough?

澳大利亚全科门诊中动脉粥样硬化性心血管疾病患者低密度脂蛋白胆固醇目标达标与他汀类药物使用:我们做得足够吗?

2026-01-010
OA
Australian Atherosclerosis Society Position Statement on Lipoprotein(a): Clinical and Implementation Recommendations (vol 32, pg 287, 2023)
2026-01-010
PRE
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial

Zodasiran,一种靶向ANGPTL3的RNAi疗法,用于治疗纯合子家族性高胆固醇血症患者(GATEWAY):一项开放标签、随机、II期临床试验

2025-12-180
PRE
Enhancing the detection of familial hypercholesterolaemia in general practice: A model for supporting genetic cascade testing in the community

增强全科实践中家族性高胆固醇血症的检测:一种支持社区遗传级联检测的模型

2025-11-170
PRE